down-regulated and 63 were up-regulated in NSCLC patients. There were no significant differences in the serum metabolite between adenocarcinoma and squamous cell carcinoma. KEGG functional annotation analysis was made on the 81 metabolites to elucidate their biological functions. Signaling pathways which might cause changes in metabolites were summarized. Conclusion: Based on our novel UPLC-MS / MS platform, more metabolites can be detected, which might provide new potential tumor biomarkers. Our study can accelerate development of new diagnostic strategies in NSCLC.
People's Hospital of Gucheng, Xiangyang/CN, 7 The First Hospital of Laohekou, Xiangyang/CN, 8 Burning Rock Biotech, Guangzhou/CN Background: TMB, measuring the number of non-synonymous mutation per megabase of DNA, has shown to associate with response to checkpoint inhibitors in a number of cancers, including lung cancer. Whole exome sequencing (WES), the gold standard for evaluating TMB, is less cost-effective. Multiple studies have shown large panels can yield comparable results in tissue samples. However, the feasibility of assessing bTMB using a large panel has not been extensively evaluated. In this study, we evaluated TMB of 30 treatment-naïve advanced NSCLC patients by performing WES on tissue samples as well as targeted sequencing on matched tissue and plasma samples. Method: WES was performed on tissue samples with an average sequencing depth of 300x. Targeted sequencing was performed on matched tissue and plasma using a panel consisting of 520 cancer-related genes, spanning 1.6Mb of human genome. An average sequencing depth of 1,000X and 10,000x were achieved for tissue and plasma samples, respectively. TMB was calculated as the ratio of mutation count to the size of coding region of the panel (1.26Mb), excluding copy number variations, fusions, large genomic rearrangements and mutations occurring on the kinase domain of EGFR and ALK. Results: In tissue samples, TMB derived from WES and our panel is comparable with a R 2 value of 0.87, and a correlation value of 0.86. CfDNA from 8 patients had no mutation detected using the 520 panel potentially due to low fraction of ctDNA present in the circulation. TMB derived from cfDNA of the remaining 22 patients showed a good correlation with TMB derived from tissue using either our panel (R 2 ¼0.94, correlation ¼0.93) or WES (R 2 ¼ 0.85, correlation¼0.87), demonstrating the feasibility of assessing TMB from cfDNA using a large panel. Next, using TMB calculated from WES as gold standard, we attempted to derive a cutoff to stratify TMB high patients from TMB low patients. Our data revealed 15 mutations per mb as an optimal cutoff using the 520 panel, achieving an AUC of 97.6% for tissue samples and 97.2% for plasma samples. Conclusion: Our study demonstrated the feasibility of evaluating TMB from cfDNA using a large panel, opening the avenue of TMB estimation using liquid biopsy. Further validations in prospective clinical trials are needed to solidify its predictive value in response to immunotherapy. Keyword: blood tumor mutation burden, liquid biopsy Background: The Lung-molGPA index is based on the original diagnosis-specific graded prognostic assessment (DS-GPA) and incorporates recently reported gene alteration data for non-small cell lung cancer (NSCLC) patients with brain metastases (BM). However, the prognostic value of the DS-GPA and Lung-molGPA models remains undetermined, especially for patients with different molecular types. Method: A total of 1,184 NSCLC patients with BM were analyzed for clinical factors and outcomes at Zhejiang Cancer Hospital, China. All prognostic factors were weighted for significance by hazard ratios. The applicability of DS-GPA and Lung-molGPA were reappraised in NSCLC patients with BM and various genetic profiles. Additionally, a modified Lung-molGPA was newly developed for NSCLC patients with gene variations. Results: NSCLC patients in the present study had a median survival time of 14.0 months from BM diagnosis. Both the DS-GPA and Lung-molGPA models predicted the patients' outcomes (P<0.001), although the Lung-molGPA model appeared to deliver more accurate predictions. Furthermore, Lung-molGPA scores demonstrated discriminatory capability in patients with gene variations (P<0.001). However, no significant difference was reached in wild-type patients (P¼0.133). Regarding oncogene-positive NSCLC patients with BM, a modified Lung-molGPA index was established based on the prognostic factors with a C-index of 0.73 (95% CI: 0.68-0.80) to accurately calculate survival probability (P<0.001). Conclusion: In the era of precision medicine, Lung-molGPA accurately predicted the prognosis of NSCLC patients with mutant genotypes and BM, although it did not perform well in wild-type patients. Thus, it is worthwhile to explore the prognostic model for patients with positive driving genes. Keywords: NonSmall Cell Lung Cancer, brain metastases, Lung-molGPA, Prediction But there is still limited evidence on its combination with chemotherapy as first line treatment in the metastatic setting. Hence, we performed a meta-analysis of randomized controlled trials that compared the efficacy and safety of combining pembrolizumab with chemotherapy versus chemotherapy alone as first line therapy for advanced non-small cell lung cancer. Method: Extensive search of PubMed, Medline and Cochrane was done for articles published after 2015. Studies were limited to RCTs comparing combined pembrolizumab and chemotherapy VS chemotherapy alone as first line treatment in advanced NSCLC. Outcomes measured included overall survival and progression-free survival in 5 yrs and 10 yrs. Statistical analysis was done using Review manager V5.3. Results: For pembrolizumab plus chemotherapy VS chemotherapy alone, pooled odds ratio of overall survival in 5 yrs and 10 yrs were 0.62 (95% CI: 0.21-
